메뉴 건너뛰기




Volumn 5, Issue 1, 2010, Pages 105-109

Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: Results of the west japan thoracic oncology group trial (WJTOG0401)

(18)  Kaneda, Hiroyasu a,b   Okamoto, Isamu a   Hayashi, Hidetoshi c   Yoshioka, Hiroshige c   Miyazaki, Masaki a   Kudoh, Shinzoh d   Kimura, Tatsuo d   Sugiura, Takamune a,b   Sawa, Toshiyuki e   Takeda, Koji f   Iwamoto, Yasuo g   Satouchi, Miyako h   Akita, Kenji i   Saito, Hiroshi j   Goto, Isao k   Shibata, Kazuhiko l   Fukuoka, Masahiro a   Nakagawa, Kazuhiko a  


Author keywords

Amrubicin; Non small cell lung cancer (NSCLC); Platinum refractory; Second line chemotherapy

Indexed keywords

AMRUBICIN; ANTINEOPLASTIC AGENT; DOCETAXEL; ERLOTINIB; GEFITINIB;

EID: 76149117204     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c07c6c     Document Type: Article
Times cited : (16)

References (21)
  • 2
    • 84971581087 scopus 로고
    • Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
    • Non-small Cell Lung Cancer Collaborative Group
    • Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
    • (1995) BMJ , vol.311 , pp. 899-909
  • 3
    • 1342268525 scopus 로고    scopus 로고
    • American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
    • American Society of Clinical Oncology
    • Pfister DG, Johnson DH, Azzoli CG, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
    • (2004) J Clin Oncol , vol.22 , pp. 330-353
    • Pfister, D.G.1    Johnson, D.H.2    Azzoli, C.G.3
  • 4
    • 0034069620 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    • Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
    • (2000) J Clin Oncol , vol.18 , pp. 2095-2103
    • Shepherd, F.A.1    Dancey, J.2    Ramlau, R.3
  • 5
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • National Cancer Institute of Canada Clinical Trials Group
    • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues Pereira, J.2    Ciuleanu, T.3
  • 6
    • 34247871456 scopus 로고    scopus 로고
    • Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: A systematic review and practice guideline
    • Noble J, Ellis PM, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2006;1:1042-1058.
    • (2006) J Thorac Oncol , vol.1 , pp. 1042-1058
    • Noble, J.1    Ellis, P.M.2    MacKay, J.A.3    Evans, W.K.4
  • 7
    • 0032445062 scopus 로고    scopus 로고
    • A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex
    • Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 1998;89: 1229-1238.
    • (1998) Jpn J Cancer Res , vol.89 , pp. 1229-1238
    • Hanada, M.1    Mizuno, S.2    Fukushima, A.3    Saito, Y.4    Noguchi, T.5    Yamaoka, T.6
  • 8
    • 0031786266 scopus 로고    scopus 로고
    • Cytotoxicity of amrubicin, A novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells
    • Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998; 89:1067-1073.
    • (1998) Jpn J Cancer Res , vol.89 , pp. 1067-1073
    • Yamaoka, T.1    Hanada, M.2    Ichii, S.3    Morisada, S.4    Noguchi, T.5    Yanagi, Y.6
  • 9
  • 12
    • 0024536437 scopus 로고
    • Optimal two-stage designs for phase II clinical trials
    • Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
    • (1989) Control Clin Trials , vol.10 , pp. 1-10
    • Simon, R.1
  • 15
    • 34547654536 scopus 로고    scopus 로고
    • Amrubicin for non-smallcell lung cancer and small-cell lung cancer
    • Kurata T, Okamoto I, Tamura K, Fukuoka M. Amrubicin for non-smallcell lung cancer and small-cell lung cancer. Invest New Drugs 2007;25: 499-504.
    • (2007) Invest New Drugs , vol.25 , pp. 499-504
    • Kurata, T.1    Okamoto, I.2    Tamura, K.3    Fukuoka, M.4
  • 16
    • 33644838068 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer
    • Okamoto I, Hamada A, Matsunaga Y, et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pharmacol 2006; 57:282-288.
    • (2006) Cancer Chemother Pharmacol , vol.57 , pp. 282-288
    • Okamoto, I.1    Hamada, A.2    Matsunaga, Y.3
  • 17
    • 0034095853 scopus 로고    scopus 로고
    • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
    • The TAX 320 Non-small Cell Lung Cancer Study Group
    • Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
    • (2000) J Clin Oncol , vol.18 , pp. 2354-2362
    • Fossella, F.V.1    Devore, R.2    Kerr, R.N.3
  • 18
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
    • (2004) J Clin Oncol , vol.22 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3
  • 19
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
    • Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3
  • 20
    • 56749131841 scopus 로고    scopus 로고
    • Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402
    • Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-5406.
    • (2008) J Clin Oncol , vol.26 , pp. 5401-5406
    • Inoue, A.1    Sugawara, S.2    Yamazaki, K.3
  • 21
    • 34247197121 scopus 로고    scopus 로고
    • Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301
    • Thoracic Oncology Research Group Study 0301
    • Onoda S, Masuda N, Seto T, et al.; Thoracic Oncology Research Group Study 0301. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-5453.
    • (2006) J Clin Oncol , vol.24 , pp. 5448-5453
    • Onoda, S.1    Masuda, N.2    Seto, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.